This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Teva Provides 2013 Non-GAAP Financial Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2013.

Financial Targets:
  • Total net revenues of between $19.5-$20.5 billion, consisting of:
Region   Net Revenues
United States   $10.0 to $10.6B
Europe   $5.5 to $6.1B
Rest of World   $3.7 to $4.3B
  • Total net revenues include the following major business lines:
  • Generic medicines (including API) net revenues of between $10.3-$10.7 billion, consisting of:
Generic   Net Revenues
United States   $4.3 to $4.7B
Europe   $3.3 to $3.7B
Rest of World   $2.4 to $2.8B
  • Brand medicines net revenues of between $7.6-$8.0 billion including estimated global net revenues of the following products:
Branded   Net Revenues
COPAXONE®   $3.7 to $3.9B
TREANDA®   $600 to $700M
Women's Health   $460 to $500M
ProAir® HFA   $400 to $440M
AZILECT®   $340 to $380M
QVAR®   $320 to $360M
NUVIGIL®   $280 to $320M
  • OTC net revenues of between $0.9-$1.1 billion
  • Other net revenues, mostly distribution of third party products, of approximately $0.7-$0.9 billion.
  • Non-GAAP gross profit margin (which excludes amortization of intangible assets of approximately $1.1 billion) of between 59% and 61%, consisting of:
Business Line  

Gross Profit Margin(% of total net sales for the line)
Generic   45% to 47%
Branded (excl Copaxone)   84% to 86%
MS   89% to 91%
  • Net R&D expenses of between 6.6% and 7.0% of net revenues, consisting of:
Business Line  

R&D Expenses(% of total net sales for the line)
Generic   $500 to $550M
Branded (excl Copaxone)   $650 to $700M
MS   $130 to $200M
  • Non-GAAP selling & marketing expenses (which excludes amortization of intangible assets) of between 19.5% and 21.5% of net revenues, including royalties of approximately $500 million, and consisting of:
Business Line  

S&M Expenses(% of total net sales for the line)
Generic   18.3% to 18.7%
Branded (excl Copaxone)   34% to 38%
MS   14.3% to 15.3%
  • General and administrative expenses of between 5.8% and 6.2% of net sales.
  • Non-GAAP net financial expenses of between $300 and $330 million.
  • Non-GAAP diluted earnings per share of between $4.85 and $5.15.*
  • Estimated fully diluted average number of shares of between 856 and 866 million.
  • Tax provision on our non-GAAP pretax income of between 14.0% and 15.0%.
  • Cash flow from operations of between $4.5 and $4.8 billion. Free cash flow (cash flow from operations minus capital expenditures and dividends) of between $2.5 and $2.8 billion.

These estimates reflect management`s current expectations for Teva's performance in 2013. Actual results may vary, whether as a result of FX differences, market conditions or other factors. In addition, the non-GAAP figures exclude the amortization of purchased intangible assets, costs related to certain regulatory actions, inventory step-up, legal settlements and reserves, impairments and related tax effects. The non-GAAP data presented by Teva are the results used by Teva's management and board of directors to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management. Teva provides such non-GAAP data to investors as supplemental data and not in substitution or replacement for GAAP results, because management believes such data provides useful information to investors. Except as expressly required by law, Teva disclaims and intent or obligation to update these statements.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs